Last update :
11/08/2022
Anti-inflammatory   Hydrocortisone sodium succinate  
Injection
Oral solution
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Actocortina Spain
Androcortil Brazil
Corticina Venezuela
Cortop Italy
Drosodin Mexico
Efcortesol Great Britain
Extaden Mexico
Flebocortid Italy, Mexico, Morocco
Fridalit Argentina, Peru
Hialub Chile
Hycort Venezuela
Hydrocort France
Inotid Mexico
Itrocsona Colombia
Novocortil Peru
Solu Cortef Australia, Belgium, Canada, Chile, Colombia, Croatia, Denmark, Finland, Great Britain, Greece, Iceland, Italy, Luxembourg, Netherlands, Norway, Portugal, Republic of South Africa, Saudi Arabia, Sweden, Switzerland, United Arab Emirates, United States of America
Sonatalis Mexico
Stricort Malaysia, Venezuela
Stability of mixtures   Injection   Stability of mixtures : Hydrocortisone sodium succinate     
Container Solvent Concentration Compound Temperature Storage Duration References
Glass Elliott’s B solution 0,478 mg/ml
Injection   Hydrocortisone sodium succinate   
Injection   Methotrexate sodium 0,0314 mg/ml
Injection   Cytarabine 0,484 mg/ml
23°C
48 Hour
Not specified 1661
Level of evidence B
Glass Elliott’s B solution 0,467 mg/ml
Injection   Hydrocortisone sodium succinate   
Injection   Methotrexate sodium 0,0581 mg/ml
Injection   Cytarabine 0,477 mg/ml
23°C
48 Hour
Not specified 1661
Level of evidence B
Glass Elliott’s B solution 0,489 mg/ml
Injection   Hydrocortisone sodium succinate   
Injection   Methotrexate sodium 0,0721 mg/ml
Injection   Cytarabine 0,479 mg/ml
23°C
48 Hour
Not specified 1661
Level of evidence B
Glass Elliott’s B solution 0,478 mg/ml
Injection   Hydrocortisone sodium succinate   
Injection   Methotrexate sodium 0,0314 mg/ml
Injection   Cytarabine 0,484 mg/ml
4°C
48 Hour
Not specified 1661
Level of evidence B
Glass Elliott’s B solution 0,467 mg/ml
Injection   Hydrocortisone sodium succinate   
Injection   Methotrexate sodium 0,0581 mg/ml
Injection   Cytarabine 0,477 mg/ml
4°C
48 Hour
Not specified 1661
Level of evidence B
Glass Elliott’s B solution 0,489 mg/ml
Injection   Hydrocortisone sodium succinate   
Injection   Methotrexate sodium 0,0721 mg/ml
Injection   Cytarabine 0,479 mg/ml
4°C
48 Hour
Not specified 1661
Level of evidence B
Glass None 10 mg/ml
Injection   Hydrocortisone sodium succinate   
Injection   Metronidazole 5 mg/ml
25°C
7 Day
Protect from light 631
Level of evidence D
Glass None 10 mg/ml
Injection   Hydrocortisone sodium succinate   
Injection   Metronidazole 5 mg/ml
5°C
12 Day
Protect from light 631
Level of evidence D
Polypropylen Syringe NaCl 0,9% or Glucose 5% 2 mg/ml
Injection   Hydrocortisone sodium succinate   
Injection   Methotrexate sodium 1 mg/ml
Injection   Cytarabine 4,1 mg/ml
25°C
24 Hour
Not specified 1028
Level of evidence A
Polypropylen Syringe Sodium chloride 0,9% 2,5 mg/ml
Injection   Hydrocortisone sodium succinate   
Injection   Methotrexate sodium 3 mg/ml
24-26°C
24 Hour
Protect from light 4641
Level of evidence A+
Polypropylen Syringe Sodium chloride 0,9% 4 mg/ml
Injection   Hydrocortisone sodium succinate   
Injection   Methotrexate sodium 6 mg/ml
24-26°C
24 Hour
Protect from light 4641
Level of evidence A+
Polypropylen Syringe Ringer’s lactate solution 2 mg/ml
Injection   Hydrocortisone sodium succinate   
Injection   Methotrexate sodium 1 mg/ml
Injection   Cytarabine 4,1 mg/ml
25°C
24 Hour
Not specified 1028
Level of evidence A
Polypropylen Syringe Elliott’s B solution 2 mg/ml
Injection   Hydrocortisone sodium succinate   
Injection   Methotrexate sodium 1 mg/ml
Injection   Cytarabine 4,1 mg/ml
25°C
24 Hour
Not specified 1028
Level of evidence A

  Mentions Légales